Project 2 - Airway Smooth Muscle Bitter Taste Receptors as Targets for Novel Bronchodilators
项目 2 - 气道平滑肌苦味受体作为新型支气管扩张剂的靶点
基本信息
- 批准号:10683126
- 负责人:
- 金额:$ 38.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-15 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylcholineActinsAdrenergic AgentsAffectAgonistAntibodiesArrestinsAsthmaBar CodesBindingBiochemicalBiologyBronchial SpasmBronchodilationBronchodilator AgentsCaringCell ProliferationCell physiologyCellsCharacteristicsClinicalCodeComplexCouplingCyclic AMPCytometryDataDevelopmentDimensionsDiseaseDown-RegulationEffectivenessEndothelin-1EventF-ActinG protein coupled receptor kinaseG-Protein-Coupled ReceptorsGTP-Binding ProteinsGoalsHealthHistamineHumanIn VitroIndividualInflammatoryKnock-outKnowledgeLIMK1 geneLinkLungMagnetismMeasurementMeasuresMechanicsMediatingMethodsModelingMolecularMolecular BiologyMolecular ConformationMolecular and Cellular BiologyMonitorMuscle relaxation phaseMutateOutcomePathway interactionsPharmaceutical PreparationsPhosphorylationPhosphorylation InhibitionPhysiologicalPhysiologyPolymersProcessProliferatingPropertyProtein IsoformsProteinsReceptor Down-RegulationReceptor SignalingRelaxationSignal TransductionSiteSliceSmall Interfering RNASmooth Muscle MyocytesStructureTachyphylaxisTaste BudsTaste PerceptionTestingTherapeutic AgentsTongueTransfectionWestern Blottinganalogasthmaticbeta-2 Adrenergic Receptorsclinically relevantcofilinconstrictiondesensitizationexperimental studyimprovedin vivoknock-downknockout genemutantnovelnovel therapeuticspolymerizationpreventreceptorreceptor downregulationreceptor expressionreceptor functionreceptor internalizationrecruitrespiratory smooth muscleresponsetherapy outcome
项目摘要
Project Summary
Bitter taste receptors (TAS2Rs) are expressed on human airway smooth muscle (HASM) and when activated
markedly relax the muscle and dilate the airway. Utilization of this pathway, which is distinct from that of β-
agonists acting at β2-adrenergic receptors (β2ARs), will provide a new class of direct bronchodilators for treating
or preventing bronchospasm in asthma. The TAS2R14 subtype is highly expressed in HASM and is a prime
target for developing a novel therapeutic agent. However, there are gaps in our knowledge about the
molecular/cellular biology and physiology of HASM TAS2Rs, including how they couple to relaxation, the
potential for tachyphylaxis due to short-term (receptor phosphorylation) and long-term (downregulation of
receptor expression) events, and the potential to bias receptor signaling towards favorable signaling for asthma
treatment. The broad, long-term objective of the Project is to improve our understanding of HASM TAS2R
biology relevant to treating airway contraction in asthma. To fill these gaps in our knowledge, in Aim 1 we will
define the mechanism by which TAS2Rs evoke relaxation, which we hypothesize is via inhibiting
phosphorylation of the actin severing protein cofilin. Studies will be performed in cultured HASM cells derived
from nonasthmatic as well as asthmatic donor lungs, the latter being important because of the potential for the
disease to modify receptor function. Studies will include siRNA-based knockouts of cofilin, and the upstream
components of the proposed pathway that link the receptor:G-protein:effector complex to cofilin. In Aim 2,
agonist-prompted phosphorylation of TAS2R14 by GRKs will be studied using whole cell phosphorylation and
receptor purification experiments. To define the precise residues phosphorylated by GRKs, TAS2R14 will be
mutated to substitute potential Ser/Thr phospho-acceptor sites with Ala, thus defining a bar-code for βarrestin
binding. The consequences of phosphorylation on βarrestin conformation and intracellular receptor
signaling, and HASM relaxation, will then be determined. In Aim 3, a panel of TAS2R14 agonists will be
utilized to determine the mechanisms by which a TAS2R agonist can be biased away from deleterious
outcomes and towards advantageous outcomes in regards to asthma therapy. This endeavor will provide the
basis for agonist-based “tuning” of the receptor to be highly efficacious in bronchodilating and inhibiting HASM
proliferation, but display little short- or long-term agonist-promoted desensitization or downregulation, such that
clinical tachyphylaxis is not apparent. All three aims will utilize parallel physiological measurements of
contraction and relaxation using nonasthmatic and asthmatic HASM cells, and an inflammatory precision-cut
human lung slice model, in order to link biochemical events to clinically relevant physiological responses.
Collectively, these studies will provide the basis for development of a novel class of direct bronchodilators
which can be utilized alone, or in combination, with β-agonists for the treatment of asthma.
项目摘要
苦味受体(TAS 2 R)在人气道平滑肌(HASM)上表达,并且当激活时,
显著放松肌肉和扩张气道。利用这一途径,这是不同于β-
作用于β2-肾上腺素能受体(β 2AR)的激动剂,将为治疗哮喘提供一类新的直接支气管扩张剂。
或预防哮喘中的支气管痉挛。TAS 2 R14亚型在HASM中高度表达,并且是HASM的主要亚型。
用于开发新型治疗剂的靶点。然而,我们对这一问题的认识还存在空白。
HASM TAS 2 R的分子/细胞生物学和生理学,包括它们如何与放松耦合,
由于短期(受体磷酸化)和长期(下调
受体表达)事件,以及将受体信号传导偏向哮喘有利信号传导的可能性
治疗该项目的广泛的长期目标是提高我们对HASM TAS 2 R的理解
与治疗哮喘气道收缩相关的生物学。为了填补这些知识空白,在目标1中,我们将
定义了TAS 2 Rs引起松弛的机制,我们假设这是通过抑制
肌动蛋白切割蛋白cofilin的磷酸化。研究将在培养的HASM细胞中进行,
来自非哮喘和哮喘供体肺,后者很重要,因为它具有治疗哮喘的潜力。
疾病改变受体功能。研究将包括基于siRNA的cofilin基因敲除,以及上游基因敲除。
将受体:G蛋白:效应子复合物与cofilin连接的拟议途径的组分。在目标2中,
将使用全细胞磷酸化研究激动剂促进的GRKs对TAS 2 R14的磷酸化,
受体纯化实验。为了确定GRK磷酸化的精确残基,将TAS 2 R14与GRK磷酸化的TAS 2 R14进行比较。
突变为用Ala取代潜在的Ser/Thr磷酸受体位点,从而定义β抑制蛋白的条形码
约束力磷酸化对β抑制蛋白构象和细胞内受体的影响
然后将确定信号传导和HASM松弛。在目标3中,将使用一组TAS 2 R14激动剂。
用于确定TAS 2 R激动剂可以偏离有害的
在哮喘治疗方面取得了良好的效果。这一奋进将提供
基于激动剂的受体“调节”在支气管扩张和抑制HASM中高度有效的基础
增殖,但几乎不显示短期或长期激动剂促进的脱敏或下调,
临床快速耐受性不明显。所有这三个目标将利用并行的生理测量,
使用非哮喘和哮喘HASM细胞的收缩和舒张,以及炎症精确切割,
人肺切片模型,以便将生化事件与临床相关的生理反应联系起来。
总的来说,这些研究将为开发一类新型的直接支气管扩张剂提供基础
其可单独使用或与β-激动剂组合使用以治疗哮喘。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen B Liggett其他文献
Stephen B Liggett的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen B Liggett', 18)}}的其他基金
Characterization of biased airway smooth muscle TAS2R agonists for treating asthma
偏向气道平滑肌 TAS2R 激动剂治疗哮喘的表征
- 批准号:
10322110 - 财政年份:2021
- 资助金额:
$ 38.89万 - 项目类别:
Characterization of biased airway smooth muscle TAS2R agonists for treating asthma
偏向气道平滑肌 TAS2R 激动剂治疗哮喘的表征
- 批准号:
10543121 - 财政年份:2021
- 资助金额:
$ 38.89万 - 项目类别:
Molecular properties of B-adrenergic receptors in Asthma
哮喘中 B-肾上腺素能受体的分子特性
- 批准号:
9130410 - 财政年份:2015
- 资助金额:
$ 38.89万 - 项目类别:
Project 2 - Airway Smooth Muscle Bitter Taste Receptors as Targets for Novel Bronchodilators
项目 2 - 气道平滑肌苦味受体作为新型支气管扩张剂的靶标
- 批准号:
10465061 - 财政年份:2013
- 资助金额:
$ 38.89万 - 项目类别:
Project 2 - Airway Smooth Muscle Bitter Taste Receptors as Targets for Novel Bronchodilators
项目 2 - 气道平滑肌苦味受体作为新型支气管扩张剂的靶标
- 批准号:
10238021 - 财政年份:2013
- 资助金额:
$ 38.89万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
7783557 - 财政年份:2010
- 资助金额:
$ 38.89万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
8403707 - 财政年份:2010
- 资助金额:
$ 38.89万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
8197661 - 财政年份:2010
- 资助金额:
$ 38.89万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
8010837 - 财政年份:2010
- 资助金额:
$ 38.89万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
8544624 - 财政年份:2010
- 资助金额:
$ 38.89万 - 项目类别:
相似海外基金
A novel motility system driven by two classes of bacterial actins MreB
由两类细菌肌动蛋白 MreB 驱动的新型运动系统
- 批准号:
22KJ2613 - 财政年份:2023
- 资助金额:
$ 38.89万 - 项目类别:
Grant-in-Aid for JSPS Fellows
The structural basis of plasmid segregation by bacterial actins
细菌肌动蛋白分离质粒的结构基础
- 批准号:
342887 - 财政年份:2016
- 资助金额:
$ 38.89万 - 项目类别:
Operating Grants
The structural basis for plasmid segregation by bacterial actins
细菌肌动蛋白分离质粒的结构基础
- 批准号:
278338 - 财政年份:2013
- 资助金额:
$ 38.89万 - 项目类别:
Operating Grants
Cytoplasmic Actins in Maintenance of Muscle Mitochondria
细胞质肌动蛋白在维持肌肉线粒体中的作用
- 批准号:
8505938 - 财政年份:2012
- 资助金额:
$ 38.89万 - 项目类别:
Differential Expression of the Diverse Plant Actins
多种植物肌动蛋白的差异表达
- 批准号:
7931495 - 财政年份:2009
- 资助金额:
$ 38.89万 - 项目类别:
Studies on how actins and microtubules are coordinated and its relevancy.
研究肌动蛋白和微管如何协调及其相关性。
- 批准号:
19390048 - 财政年份:2007
- 资助金额:
$ 38.89万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Interaction of myosin with monomeric actins
肌球蛋白与单体肌动蛋白的相互作用
- 批准号:
5311554 - 财政年份:2001
- 资助金额:
$ 38.89万 - 项目类别:
Priority Programmes
STRUCTURE/INTERACTIONS OF ACTINS AND ACTIN-BINDING PROTEIN
肌动蛋白和肌动蛋白结合蛋白的结构/相互作用
- 批准号:
6316669 - 财政年份:2000
- 资助金额:
$ 38.89万 - 项目类别: